erlotinib_adrHCC827_diffexDT: Microarray assay to understand acquired drug resistance to...
In adamsardar/metaDEGth: Combining differential expression P-values in a statistically consistent fashion whilst respecting background signal/noise trends
erlotinib_adrHCC827_diffexDT R Documentation
Microarray assay to understand acquired drug resistance to EGFR-targeted therapy (erlotinib) in cell lines
Description
GSE38310: HCC827 cell lines, which are susceptible to erlotinib, were treated to induce resistence in vivo by repeated exposure. Gene expression of cell lines
treated with erlotibin was collected (alongside controls) in both susceptible and resistant cell lines. Expression captured using Illumina HumanHT-12 V3.0 expression beadchip.
Usage
data(erlotinib_adrHCC827_diffexDT)
Format
A data.table with 48,803 rows, documenting probe-level differential expression in three erlotinib-treated cell lines: HCC827 (susceptible) and against ER3/T15.2 (evolved resistance). Additional gene symbols, entrez gene IDs and uniprot annotations also included.
Details
The study authors cocluded that AXL kinase caused resistance to EGFR therapy. A clean peturbagenic experiment.
Generated 10 December 2019 from raw expression values dowloaded from GEO. Values were normalised using limma::neqc and processed with further limma functions.
Source
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE38310
References
https://en.wikipedia.org/wiki/Erlotinib
Zhang Z, Lee JC, Lin L, Olivas V et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012
adamsardar/metaDEGth documentation built on Sept. 28, 2022, 10:12 p.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
| erlotinib_adrHCC827_diffexDT | R Documentation |
Microarray assay to understand acquired drug resistance to EGFR-targeted therapy (erlotinib) in cell lines
Description
GSE38310: HCC827 cell lines, which are susceptible to erlotinib, were treated to induce resistence in vivo by repeated exposure. Gene expression of cell lines treated with erlotibin was collected (alongside controls) in both susceptible and resistant cell lines. Expression captured using Illumina HumanHT-12 V3.0 expression beadchip.
Usage
data(erlotinib_adrHCC827_diffexDT)
Format
A data.table with 48,803 rows, documenting probe-level differential expression in three erlotinib-treated cell lines: HCC827 (susceptible) and against ER3/T15.2 (evolved resistance). Additional gene symbols, entrez gene IDs and uniprot annotations also included.
Details
The study authors cocluded that AXL kinase caused resistance to EGFR therapy. A clean peturbagenic experiment.
Generated 10 December 2019 from raw expression values dowloaded from GEO. Values were normalised using limma::neqc and processed with further limma functions.
Source
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE38310
References
https://en.wikipedia.org/wiki/Erlotinib
Zhang Z, Lee JC, Lin L, Olivas V et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.